Acasti Pharma (NASDAQ:ACST) Research Coverage Started at CIBC

Share on StockTwits

CIBC initiated coverage on shares of Acasti Pharma (NASDAQ:ACST) in a report published on Thursday, FirstToMarketsRatingsTable reports. The brokerage issued an outperform rating and a $7.00 target price on the biopharmaceutical company’s stock.

ACST has been the topic of several other research reports. Zacks Investment Research downgraded shares of Home Bancshares from a hold rating to a sell rating in a research note on Friday, June 7th. Aegis assumed coverage on shares of Acasti Pharma in a research note on Tuesday, July 9th. They set a buy rating on the stock. Oppenheimer reaffirmed a market perform rating on shares of Waste Management in a research note on Thursday. ValuEngine raised shares of WPP from a sell rating to a hold rating in a research note on Wednesday, June 19th. Finally, HC Wainwright reissued a buy rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th. Six equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus target price of $5.25.

Acasti Pharma stock opened at $1.71 on Thursday. Acasti Pharma has a 12-month low of $0.43 and a 12-month high of $1.80. The business’s fifty day moving average price is $1.13.

An institutional investor recently bought a new position in Acasti Pharma stock. Geode Capital Management LLC bought a new position in Acasti Pharma Inc (NASDAQ:ACST) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 48,665 shares of the biopharmaceutical company’s stock, valued at approximately $40,000. Geode Capital Management LLC owned about 0.06% of Acasti Pharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 3.12% of the company’s stock.

Acasti Pharma Company Profile

Acasti Pharma Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia.

Featured Story: Buyback For Investors Defined

Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report